Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Biotek-snakken
  4. Biotek-snakken — Maj 2024

Biotek-snakken — Maj 2024

Planlagt Fastgjort Låst Flyttet Biotek-snakken
67 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • F Offline
    F Offline
    Fandel
    wrote on sidst redigeret af
    #32

    Godmorgen...

    1 Reply Last reply
    0
    • L Offline
      L Offline
      LP90
      wrote on sidst redigeret af
      #33

      Godmorgen 🙂

      1 Reply Last reply
      0
      • exitnuE Offline
        exitnuE Offline
        exitnu
        wrote on sidst redigeret af
        #34

        Calliditas’ Partner Everest Medicines Starts Commercial Launch of Nefecon in China

        Link Preview Image
        Calliditas Therapeutics AB

        Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

        favicon

        Calliditas Therapeutics AB (www.calliditas.se)

        1 Reply Last reply
        0
        • exitnuE Offline
          exitnuE Offline
          exitnu
          wrote on sidst redigeret af
          #35

          “This is a fantastic result from many years of dedication and hard work by teams from both companies and I am delighted that patients in China now can benefit from Nefecon, which has been specifically designed to address the origin of IgAN,” said Renee Aguiar-Lucander, CEO.

          1 Reply Last reply
          0
          • F Offline
            F Offline
            Fandel
            wrote on sidst redigeret af
            #36

            Godmorgen...

            1 Reply Last reply
            0
            • L Offline
              L Offline
              LP90
              wrote on sidst redigeret af
              #37

              Morning 🙂

              1 Reply Last reply
              0
              • exitnuE Offline
                exitnuE Offline
                exitnu
                wrote on sidst redigeret af
                #38

                Genovis - Interim Report January – March 2024

                https://mb.cision.com/Main/1712/3976051/2798815.pdf

                "Best quarter for enzyme business in analytics and stronger cash position"

                1 Reply Last reply
                0
                • F Offline
                  F Offline
                  Fandel
                  wrote on sidst redigeret af
                  #39

                  Godmorgen...

                  1 Reply Last reply
                  0
                  • L Offline
                    L Offline
                    LP90
                    wrote on sidst redigeret af
                    #40

                    Morning 🙂

                    1 Reply Last reply
                    0
                    • F Offline
                      F Offline
                      Fandel
                      wrote on sidst redigeret af
                      #41

                      Godmorgen...

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        LP90
                        wrote on sidst redigeret af
                        #42

                        Godmorgen 🙂

                        1 Reply Last reply
                        0
                        • D Offline
                          D Offline
                          DECIDE
                          wrote on sidst redigeret af
                          #43

                          Nanexa ser interessant ud.

                          1 Reply Last reply
                          0
                          • D Offline
                            D Offline
                            DECIDE
                            wrote on sidst redigeret af
                            #44

                            Deres PharmaShell teknologi kunne være godt bud på Long acting injectables for en række lægemidler. Har projekt med liraglutid. Desuden muligt partnerskab med Novo Nordisk, mon ikke glp1/sema, men undisclosed Her ligger upside især og Novo skal snart beslutte, om de vil indgå licensaftale. Lav marketcap., høj
                            risiko, stor upside.

                            1 Reply Last reply
                            0
                            • D Offline
                              D Offline
                              DECIDE
                              wrote on sidst redigeret af
                              #45

                              Xspray en en anden jeg har øje til. Dasynoc har PDUFA dato 31. juli i år. Høj
                              risiko også, men kan blive stort.

                              1 Reply Last reply
                              0
                              • D Offline
                                D Offline
                                DECIDE
                                wrote on sidst redigeret af
                                #46

                                Som en sidste vil jeg nævne BioInvent. Har efterhånden 5 molekyler i klinikken, og der venter et meget spændende år med mange data, særlig på
                                BI1808 og BI1206.

                                1 Reply Last reply
                                0
                                • D Offline
                                  D Offline
                                  DECIDE
                                  wrote on sidst redigeret af
                                  #47

                                  Hører gerne fra andre om de tre selskaber og jeres vurdering.

                                  1 Reply Last reply
                                  0
                                  • exitnuE Offline
                                    exitnuE Offline
                                    exitnu
                                    wrote on sidst redigeret af
                                    #48

                                    Calliditas Therapeutics - Calliditas Q1 report, January – March 2024:

                                    Link Preview Image
                                    Calliditas Therapeutics AB

                                    Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

                                    favicon

                                    Calliditas Therapeutics AB (www.calliditas.se)

                                    1 Reply Last reply
                                    0
                                    • exitnuE Offline
                                      exitnuE Offline
                                      exitnu
                                      wrote on sidst redigeret af
                                      #49

                                      Target market expansion following full approval in the US

                                      Net sales amounted to SEK 295.5 million, of which TARPEYO® net sales amounted to SEK 278.3 million, for the three months ended March 31, 2024. For the three months ended March 31, 2023, net sales amounted to SEK 191.4 million, of which TARPEYO net sales amounted to SEK 185.7 million.

                                      1 Reply Last reply
                                      0
                                      • exitnuE Offline
                                        exitnuE Offline
                                        exitnu
                                        wrote on sidst redigeret af
                                        #50

                                        “In Q1 we generated another record quarter in terms of demand with 705 enrollments and 354 new prescribers. We are very excited over this positive trend, and we continue to see strong demand in Q2.” – CEO Renée Aguiar-Lucander.

                                        1 Reply Last reply
                                        0
                                        • exitnuE Offline
                                          exitnuE Offline
                                          exitnu
                                          wrote on sidst redigeret af
                                          #51

                                          Calliditas Q1: A powerful Tarpeyo launch momentum

                                          Just a moment...

                                          favicon

                                          (www.redeye.se)

                                          (Redeye)

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper